The present invention relates to gentiopicroside free Gentiana acaulis and/or Gentiana septemfida extracts. Furthermore, it relates to cosmetic compositions comprising such gentiopicroside free Gentiana acaulis or Gentiana septemfida extract, as well as mixtures thereof.

The invention relates to a method for extraction and separation of cannabinoids from industrial hemp, designed for medicinal purposes, and also the preparation of an extract, not containing tetrahydrocannabinol, and the preparation of maximum refined individual cannabinoids.

The advantage of the method according to the invention consists in the preparation of an extract from hemp, which contains at a high percentage medically useful cannabinoids and doesn't contain undesirable admixtures and tetrahydrocannabinol, so that it can be used without any restrictions as a pharmaceutical. Moreover, the method allows the possibility of separation, if required, into individual useful cannabinoids as pure compounds, in ecological terms, without environmental pollution, as it is according to the most synthetic methods. The possibility of producing pure compounds represents a great contribution to the research of substances, related to a concrete medical application and the preparation of various combinations thereof, with the objective of expansion the field of application. The method is also cost-effective.

The method consists in that the extract, obtained in accordance with various methods, undergoes a centrifugal countercurrent liquid-liquid chromatography, as the operation includes a centrifugation of solvents and the extract, obtained during the previous operations; the solvents form two phases, the phase, which the extract is dissolved in, is mobile, and the other one is stationary, whereby the mobile phase passes through the stationary phase, wherein several amounts of the components of the extract content are captured; this passing of the mobile phase through the stationary phase is repeated many times, until separation of the desired substances, which are analyzed in a familiar way, whereby as stationary phase solvents are used, which are selected from the group of straight-chain and branched-chain hydrocarbons, produced from crude oil, straight-chain and/or branched-chain alcohols, straight-chain and/or branched-chain ketones, straight-chain and/or branched chain carboxylic acids, straight-chain and/or branched-chain nitriles, gases in supercritical and subcritical condition, like carbon dioxide, nitrogen, nitrogen oxides, water with modified acidity with or without salts of organic and non-organic substances dissolved therein, as for example NaSO.sub.3, carbonate compounds or mixtures of the above-mentioned solvents, and as mobile phase solvents are used, which are selected from the group of straight-chain and branched-chain hydrocarbons, produced from crude oil, straight-chain and/or branched-chain alcohols, straight-chain and/or branched-chain k

A method for making a caffeoylquinic composition from a botanical source is disclosed. The method may include chromatographing an extract of biomass on an ion exchange stationary phase and obtaining an eluent comprising a caffeoylquinic composition. The biomass may be Stevia or yerba mate, for example. The caffeoylquinic composition includes one or more of monocaffeoylquinic acid, dicaffeoylquinic acid, and salts of the foregoing.

A purified lipid-based solution including cannabinoids is manufactured by providing a lipid solution including an array of triglycerides, cannabinoids and water soluble contaminants. Adding water to the lipid solution to create a mixture and heating the mixture in a pressure vessel to a temperature above the melting point of the lipid solution. The mixture is agitated to dissolve the water soluble contaminants and electrocoagulated. The mixture is cooled to cause the triglycerides and cannabinoids to solidify. The water is separated from the mixture to remove water soluble contaminants, precipitated contaminants, suspended solids and colloids from the mixture to yield a purified lipid solution.

The present disclosure provides a drug for treating prostatitis or benign prostatic hyperplasia (BPH), including sulforaphane (SFA) or an SFA-containing plant extract. In the present disclosure, the SFA, as an active ingredient, is isolated from a plant of Brassica. The plant of Brassica includes, but is not limited to, Raphanus sativus L., Brassica oleracea L. var. italica Plenck, Brassica oleracea, and Brassica juncea (L.) Czern.

The present invention relates to a pharmaceutical composition for preventing or treating voiding dysfunction and a health functional food for preventing or improving of voiding dysfunction, comprising extract of Piper Longum L. as an active ingredient. The extract of Piper Longum L. according to the present invention is not only harmless, but also has outstanding effects of preventing, treating and improving voiding dysfunction by being involved in various mechanisms related to voiding dysfunction simultaneously so that it may increase a micturition interval, decrease a micturition pressure, increase a bladder capacity, inhibit detrusor contraction and induce relaxation of detrusor.

A method for extracting cannabinoids from plant material containing one or more cannabinoids including: (1) shredding the plant material into an appropriate size; (2) soaking the shredded plant material in a polar solvent to dissolve the one or more cannabinoids into the alcohol to form a polar solvent/cannabinoid mixture; (3) separating the polar solvent/cannabinoid mixture from residual solid plant material; (4) treating the polar solvent/cannabinoid mixture to a non-polar solvent to remove the one or more cannabinoids into the non-polar solvent to form a non-polar solvent/cannabinoid mixture; (5) distilling the non-polar solvent/cannabinoid mixture to separate the non-polar solvent from the one or more cannabinoids; and (6) subjecting the cannabinoid mixture to a supercritical fluid to isolate and purify the cannabinoid mixture into individual cannabinoids of the one or more cannabinoids.

A method for modifying cannabinol (CBN) to trans-9-tetrahydrocannabinol (THC) content in a lipid-based extract of cannabis to yield a low-THC product. The method includes providing a lipid-based extract of cannabis containing THC, heating the lipid-based extract at 1 atm of pressure to 157 to 160 C. to vaporize a first portion of the THC, and converting a second portion of the THC to CBN by heating the lipid-based extract to between 130 C.-150 C. for at least 10 min. In one embodiment the step of vaporizing occurs after the step of converting to remove the trans-9-tetrahydrocannabinol from the product.

A method for producing full spectrum hemp extract comprising extracting substances from Cannabis-based green material that are soluble in an extraction solvent and collecting an extract that includes the extraction solvent distilling at least a portion of the extraction solvent which results in a concentrate that is not distilled off, removing at least a portion of water soluble substances from the concentrate by partitioning the at least a portion of water soluble substances into an aqueous phase and a remainder of substances from the concentrate into a partitioned concentrate, heating the partitioned concentrate to evaporate the nonpolar solvent and to yield a crude oil, degassing the crude oil by heating it which results in a degassed crude oil, performing a first pass distillation at about 150 C. and collecting a first residue, performing a second and third pass distillation at about 170 C. and about 185 C., and collecting a distillate from same.

The present invention describes a method which outlines a process for conversion of CBD to a .sup.9-tetrahydrocannabinol (.sup.9-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the .sup.9-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% .sup.9-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce .sup.9-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% .sup.9-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the .sup.9-THC using distillation and collecting an essentially pure fraction of .sup.9-THC using additional distillation or enrichment form of purification. Included are methods and processes to scale the reaction from the lab to large scale manufacturing. Included are methods for adding a molecule marker to authenticate high purity .sup.9-THC products. Formulations and uses for pharmaceuticals, nutraceuticals, food products, and topicals are also provided.